Is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells as determined by the treating physician(s).
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/OiWA3jN
No comments:
Post a Comment